Influence of age on the pharmacokinetics of i.v. vinflunine: Results of a phase I trial in elderly cancer patients

Journal of Geriatric Oncology

Volumn 3, Issue 1, 2012, Pages 41-48

  Tourani, J M ^a   Mourey, L ^b   Servent, V ^c   Nguyen, T ^d   Ravaud, A ^e   Girre, V ^f   Favrel, S ^g   Pinel, M C ^g   Isambert, N ^h  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d CHU Jean Minoz Besançon   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

^f INSTITUT CURIE   (France)

^g INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Elderly patients; Pharmacokinetics; Phase I; Vinflunine

Indexed keywords

VINFLUNINE;

ABDOMINAL PAIN; AGE; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BRONCHITIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLATULENCE; GERIATRIC CARE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; INTESTINE OBSTRUCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYALGIA; NAUSEA; NEOPLASM; NEUROPATHIC PAIN; NEUTROPENIA; PARESTHESIA; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REFERENCE VALUE; SIDE EFFECT; STOMATITIS; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; THRUSH; VOMITING; WEIGHT REDUCTION;

EID: 84856358077     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2011.11.008     Document Type: Article

References (23)

1. Extermann M. Geriatric oncology: an overview of progresses and challenges. Cancer Res Treat 2010, 42(2):61-68.
2. Tranchand B., Falandry C., You B., Girard P., Ribba B., Tod M., et al. Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment. Bull Cancer 2008, 5077, 95 FMC Onco:F21-7.:F21-F27.
3. Jacquesy J.C., Fabry I. Superacidic generation of new antitumour agents. Biomedical chemistry: applying chemical principles to the understanding and treatment of disease 2000, 227-245. John Wiley & Sons, New York, NY. P. Torrents (Ed.).
4. Hill B.T. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des 2001, 7(13):1199-1212.
5. Etievant C., Barret J.M., Kruczynski A., Perrin D., Hill B.T. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998, 16(1):3-17.
6. Ngan V.K., Bellman K., Hill B.T., Wilson L., Jordan M.A. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001, 60(1):225-232.
7. Jean-Decoster C., Brichese L., Barret J.M., Tollon Y., Kruczynski A., Hill B.T., et al. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs 1999, 10(6):537-543.
8. Lobert S., Ingram J.W., Hill B.T., Correia J.J. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998, 53(5):908-915.
9. Culine S., Theodore C., De Santis M., Bui B., Demkow T., Lorenz J., et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006, 94(10):1395-1401.
10. Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009, 27(27):4454-4461.
11. Frampton J.E., Moen M.D. Vinflunine. Drugs 2010, 70(10):1283-1293.
12. Bennouna J., Fumoleau P., Armand J.P., Raymond E., Campone M., Delgado F.M., et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003, 14(4):630-637.
13. Vermorken J.B., Stupp R., Nguyen L. Phase I study of IV vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. Proc Am Soc Clin Oncol 2003, 4794, 22: 221 (Abstract 887).
14. Johnson P., Geldart T., Fumoleau P., Pinel M.C., Nguyen L., Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 2006, 24(3):223-231.
15. Focan C., Van Heugen J.C., Kreutz F. Vinflunine metabolism and disposition in cancer patients. Proc Am Soc Clin Oncol 2002, 495.
16. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 5078.
17. Wildiers H., Highley M.S., de Bruijn E.A., van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003, 42(14):1213-1242. 5078.
18. EMA. Studies in support of special populations: geriatrics. ICH Topic E7 10 A.D.; 1993.
19. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 5078.
20. Zorza G., Pellerin D., Fortune V., Puozzo C. A simple and sensitive high-performance liquid chromatographic method for the determination of vinflunine and 4-O-deacetylvinflunine from human blood. Ther Drug Monit 2010, 32(6):734-740.
21. Delord J.P., Isambert N., Fumoleau P., Ravaud A., Nguyen T., Ferre P., et al. Influence of renal dysfunction on the pharmacokinetic of i.v. vinflunine: results of a phase I trial in cancer patients. ASCO 2011, Abstract ID 2570.
22. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009, 41(2):67-76. 5078.
23. (R) summary of product characteristics 2011.